
# CLAIMS


1. A method of treating an individual in need thereof comprising administering a combination of a menin inhibitor and a CYP3A4 inhibitor.

2. A method of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a menin inhibitor and a pharmaceutical composition comprising a CYP3A4 inhibitor.

3. The method of any preceding claim, wherein menin inhibitor is selected from Formula (I) and Formula (II)





Formula (I),




Formula (II)

or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, geometric isomer or tautomer thereof.


4. The method of any preceding claim, wherein the menin inhibitor is a compound of Formula (I)



Formula (I),

or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, geometric isomer, or tautomer thereof.

5. The method of any preceding claim, wherein the menin inhibitor is inhibitor is a compound of Formula (II)



Formula (II),

or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, geometric isomer, or tautomer thereof.

6. The method of any preceding claim, wherein the CYP3A4 inhibitor is selected from the group consisting of boceprevir, nefazodone, clarithromycin, nelfinavir, conivaptan, posaconazole, grapefruit juice, ritonavir, indinavir, saquinavir, itraconazole, telaprevir, ketoconazole, telithromycin, lopinavir, voriconazole, cobicistat, mibefradil.

7. The method of any preceding claim, wherein the CYP3A4 is an azole antifungal.

8. The method of any preceding claim, wherein the CYP3A4 inhibitor is posaconazole.

9. The method of any preceding claim, wherein the CYP3A4 inhibitor is cobicistat.

10. The method of any preceding claim, wherein the CYP3A4 inhibitor is ketoconazole.

11. The method of any preceding claim, wherein the CYP3A4 inhibitor is ritonavir.

12. The method of any preceding claim, wherein the menin inhibitor and the CYP3A4 inhibitor are in a combined dosage form.

13. The method of any one of claims 1-11 wherein the menin inhibitor and the CYP3A4 inhibitor are in separate dosage forms.

14. The method of any preceding claim, wherein the menin inhibitor is administered in a sub-therapeutically-effective amount.

15. The method of any preceding claim, wherein the CYP3A4 inhibitor is administered in a therapeutically-effective amount.

16. The method of any claim 1-14, wherein the CYP3A4 inhibitor is administered in a sub-therapeutically-effective amount.

17. The method of any preceding claim, wherein the menin inhibitor and the CYP3A4 inhibitor are administered concurrently.

18. The method of any preceding claim, wherein the menin inhibitor and the CYP3A4 inhibitor are administered simultaneously, essentially simultaneously or within the same treatment protocol.


19. The method of any preceding claim, wherein the menin inhibitor and the CYP3A4 inhibitor are administered sequentially.

20. The method of any preceding claim, wherein the combination is administered for an initial treatment period followed by continued administration of the menin inhibitor.


21. The method of any preceding claim, wherein administration of the CYP3A4 inhibitor occurs before the administration of the menin inhibitor.

22. A kit for treating cancer in an individual comprising a combination of a menin inhibitor and a CYP3A4 inhibitor.

23. The kit of claim 22, wherein the menin inhibitor is selected from Formula (I) and Formula (II)




Formula (I),





Formula (II)

or a pharmaceutically acceptable salt, stereoisomer, geometric isomer or tautomer thereof.


24. The kit of any one of claims 22-23, further comprising instructions on how to use the kit.

25. A composition of a menin inhibitor and a CYP3A4 inhibitor, wherein the menin inhibitor and the CYP3A4 inhibitor come into contact with each other in the human body (e.g., only in the human body).

26. The composition of claim 25, wherein the menin inhibitor is selected from Formula (I) and Formula (II)




Formula (I),





Formula (II)


or a pharmaceutically acceptable salt, stereoisomer, geometric isomer or tautomer thereof..

27. A method of preparing a composition by bringing a menin inhibitor and a CYP3A4 inhibitor into contact with each other at a locus.

28. The method of claim 27, wherein the menin inhibitor is selected from Formula (I) and Formula (II)




Formula (I),




Formula (II)

or a pharmaceutically acceptable salt, stereoisomer, geometric isomer, or tautomer thereof.


29. A combination of a menin inhibitor and a CYP3A4 inhibitor used for the manufacture of a medicament for treating cancer.

30. The method of any claim 1-21, wherein CYP3A4 inhibitor is a strong CYP3A4 inhibitor.

31. A method for treating cancer in a patient comprising the steps of

a) administering a pharmaceutical composition comprising posaconazole, and

b) administering a pharmaceutical composition comprising the menin inhibitor of Formula (II)



Formula (II),

or a pharmaceutically acceptable salt thereof.

32. The method of any claim 1-21 or 31, wherein the menin inhibitor is a fumarate salt.

33. The method of any claim 1-21 or 31-32, wherein the menin inhibitor is a sesquifumarate salt.